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The protein products of the tumor suppressor genes
tuberous sclerosis complex 1 and 2 form a protein
complex, TSC1–TSC2, that inhibits growth. Several
new studies suggest that TSC1–TSC2 does this 
by inhibiting TOR and S6 kinase, and that PI 3-
kinase–Akt signaling relieves this inhibition.
How growth and cell size are controlled is poorly
understood, but receiving increasing attention from
researchers. What has become clear in recent years is
that two signal transduction pathways are major
regulators of growth (mass increase) and cell size in
organisms as diverse as insects and mammals. One of
these is the pathway involving phosphatidylinositol 3-
kinase (PI 3-kinase) and the protein kinase Akt; the
second is the pathway that responds to nutrient supply
and involves the ‘target of rapamycin’ (TOR) protein
(reviewed in [1,2]). Although these pathways are
thought to converge at some level, the mechanisms
through which this occurs have so far been elusive.
Earlier work in the fruit fly Drosophila showed that
dTsc1 and dTsc2, homologs of the human tumor sup-
pressor gene products TSC1 (also known as hamartin)
and TSC2 (also called tuberin), function as a complex
in vivo that restricts cell proliferation and reduces cell
size [3–6]. Interestingly, genetic epistasis analyses sug-
gested that dTsc1–dTsc2 acts downstream of dAkt
and upstream of the dTOR target, dS6 kinase [4–6]. A
flurry of recent research [7–14] has now confirmed
these ideas, placing TSC1–TSC2 right at the center of
the growth signaling network. Collectively, these new
papers show that TSC1–TSC2 inhibits S6 kinase by
repressing TOR activity, and that TSC1–TSC2 is phos-
phorylated and inactivated by Akt.
Studies in both mammalian cells and Drosophila
established the existence of a signaling network that
links insulin stimulation and nutrient availability to the
up-regulation of translation and cell growth (Figure 1)
[1,2]. In brief, insulin, or an insulin-like ligand, binds to
and activates its cognate receptor, resulting in activa-
tion of PI 3-kinase and consequent production of 3-
phosphoinositides. This process is antagonized by the
lipid phosphatase encoded by the tumor suppressor
gene PTEN. The increased 3-phosphoinositide level
leads to the phosphorylation and activation of the
serine/threonine kinase Akt.
The activation of PI 3-kinase–Akt signaling can have
numerous downstream effects [2]. One appears to be
the activation of S6 kinase as, for example, phospho-
rylation of a key residue in the carboxyl terminus of the
protein — threonine 389 in human S6 kinase 1 — is
sensitive to PI 3-kinase-specific inhibitors [15]. But the
precise mechanism by which PI 3-kinase–Akt signaling
influences S6 kinase activation has been somewhat
controversial. Once activated, S6 kinase phosphory-
lates ribosomal protein S6, thereby promoting transla-
tion of a specific class of mRNAs which themselves
largely encode ribosomal proteins and other proteins
involved in translation.
Phosphorylation of S6 kinase on threonine 389 is
also sensitive to the TOR inhibitor, rapamycin [15]; as
TOR is a serine/threonine kinase, this phosphorylation
event might be direct. Significantly, TOR activity is
promoted by the presence of amino acids and high
ATP concentrations, suggesting that TOR might be a
nutrient and metabolism sensor [16]. TOR is also
thought to phosphorylate 4E-BP1, an inhibitor of the
translation initiation factor eIF4E. In this case, phos-
phorylation inhibits 4E-BP1 function, thereby increas-
ing eIF4E-mediated, cap-dependent translation. The
up-regulation of protein translation thus seems to be
an important target of both PI 3-kinase–Akt and
nutrient–TOR growth signaling.
A role for TSC1–TSC2 in growth control was first
suggested by the identification of TSC1 and TSC2 as
human tumor suppressor genes (reviewed in [17]).
Loss of heterozygosity at either locus is associated
with tuberous sclerosis, a relatively common disease
involving the widespread development of benign
growths, called hamartomas, some of which contain
big cells. Genetic analyses in Drosophila confirmed the
importance of TSC1–TSC2 in growth inhibition: muta-
tion of either dTsc1 or dTsc2 enhances growth and
increases cell size, whereas co-expression of dTsc1
and dTsc2 inhibits growth and reduces cell size [3–6].
However, the structures of TSC1 and TSC2 provided
few clues as to how the TSC1–TSC2 complex might
function at the molecular level. TSC1 has a coiled-coil
region and a potential transmembrane domain, while
TSC2 has a putative GTPase-activating protein (GAP)
domain and a leucine zipper-like sequence [17].
Earlier research in Drosophila suggested that dS6
kinase might be an inhibitory target of dTsc1–dTsc2 in
growth control [4–6]. Five of the new papers [8–12]
have confirmed this idea using an array of biochemical
and molecular assays. For example, decreasing TSC2
expression by RNA interference (RNAi) increases S6
kinase phosphorylation (on the critical threonine 389
residue), whereas overproduction of TSC1–TSC2 is
sufficient to inhibit S6 kinase phosphorylation and acti-
vation [8,10]. Moreover, mammalian cells harbouring
disease-associated mutations in either TSC1 or TSC2
have constitutively high phosphorylation of both S6
kinase and its substrate S6 [9,11].
As TOR is a well-established activator of S6 kinase,
some labs went on to test whether TSC1–TSC2 might
inhibit S6 kinase indirectly via effects on TOR [8,10].
Indeed, Inoki et al. [10] found that the ability of TOR 
to stimulate S6 kinase phosphorylation is compro-
mised when TSC1–TSC2 is overproduced. Taking the
converse approach, Gao et al. [8] showed that the
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increase in dS6 kinase phosphorylation normally
observed upon reducing dTsc1–dTsc2 expression is
inhibited by attenuating dTOR activity. Significantly,
several genetic interactions in Drosophila also place
dTOR downstream of dTsc1–dTsc2 [8]. Taken together,
these observations strongly suggest that TSC1–TSC2
acts upstream of TOR to inhibit both its kinase activ-
ity and its ability to promote growth in vivo. Although
it is unclear how TSC1–TSC2 inhibits TOR, direct
association and/or phosphorylation may be important,
as dTsc2 and dTOR co-immunoprecipitate [8] and
phosphorylation of mammalian TOR is sensitive to
TSC1–TSC2 levels [10].
Consistent with the view that TOR acts as a nutrient
sensor, S6 kinase and 4E-BP1 phosphorylation nor-
mally depends on the nutritional status of the cell. Inter-
estingly, the ability of nutrient stimulation to increase S6
kinase and 4E-BP1 phosphorylation is inhibited by
overproduction of TSC1–TSC2 [10]. Conversely, the
rapid and sustained decrease in S6 kinase phosphory-
lation caused by amino acid deprivation is overcome by
reducing TSC1–TSC2 levels [8]. These observations
suggest that TSC1–TSC2 inhibits the ability of TOR to
respond to changes in amino acid/nutrient levels. Alter-
natively, TSC1–TSC2, rather than TOR, might be the
‘primary’ nutrient sensor of the cell.
Although previous genetic analyses clearly placed
dTsc1–dTsc2 downstream of dPI 3-kinase–dAkt
signaling in the fruit fly, it was not clear how this works
at the molecular level [4-6]. Several groups [7,10,12–14]
have now shown that Akt itself phosphorylates the
TSC1–TSC2 complex. Manning et al. [12] used a pow-
erful combination of bioinformatics and phospho-spe-
cific antibodies to show that Akt phosphorylates TSC2
in a PI 3-kinase-dependent manner. Furthermore, Akt
and TSC2 co-immunoprecipitate from mammalian cells
[7,12]. Sequence analysis of human TSC2 identified six
potential Akt phosphorylation sites, two of which are
conserved in Drosophila dTsc2 [12,14]. Consistent with
these two sites being important, Akt-mediated phos-
phorylation of TSC2S939A/T1462A, in which both these
residues are altered to non-phosphorylatable alanines,
is substantially reduced compared to wild-type [12,14].
Notably, Akt was found neither to bind nor phos-
phorylate TSC1 [7,10], and the role of TSC1 in the
TSC1–TSC2 complex remains unclear.
As would be predicted from genetic data [4–6], Akt-
mediated phosphorylation of TSC2 inhibits TSC1–TSC2
function. This was shown in several ways. For example,
TSC2S939A/T1462A is more effective than wild-type TSC2
at inhibiting S6 kinase and 4E-BP1 phosphorylation
[10,12]. Potter et al. [14] report equivalent results from
experiments using Drosophila wing and eye growth as
a read-out. They found that overproduction of non-
phosphorylatable dTsc2 — analogous to mammalian
TSC2S939A/T1462A — inhibited growth to a greater extent
than the wild-type protein (co-produced with dTsc1).
Strikingly, the production of this ‘dAkt-resistant’ dTsc2
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Figure 1. Generic PI 3-kinase–Akt and nutrient–TOR signaling pathways.
(A) In the absence of extracellular growth signals (‘OFF’), translation rates are low because TSC1–TSC2 inhibits TOR and 4E-BP1 inhibits
eIF4E. (B) In the presence of growth factors (‘ON’), PI 3-kinase–Akt signaling is activated. Phosphorylation of TSC2 by Akt promotes its
binding to 14-3-3 proteins, somehow inactivating the TSC1–TSC2 complex. This derepresses TOR, leading to phosphorylation of 4E-
BP1 and S6 kinase and thus increased translation. TOR activity is also promoted by nutritional inputs, though how is not clear. (See text
and [1,2] for details.) Note that this is an oversimplified model and several components have additional upstream inputs and downstream
targets not shown; for example, S6 kinase can be activated independently of PI 3-kinase-Akt [18]. Also, two new papers report that
TSC1–TSC2 inhibits S6 kinase in a TOR-independent manner [19,20]. Abbreviations: In, insulin; IGF, insulin-like growth factors; InR,
insulin/IGF receptor; IRS, insulin receptor substrate; PIP2, phosphatidylinositol-4,5-bisphosphate; PIP3, phosphatidylinositol-3,4,5-trispho-
sphate; PDK1, phosphoinositide-dependent kinase 1; 4E-BP1, eIF4E binding protein 1; eIF4E, eukaryotic initiation factor 4E; 5′ TOP, 5′
terminal oligopyrimidine tract-containing mRNA. Green arrows indicate activation and red arrows indicate inhibition. Colored or grayed
shapes represent active or inactive molecules, respectively. Circled ‘P’s represent phosphorylation events.
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completely suppressed the ability of overproduced
dAkt to promote growth and increase cell size. More-
over, overproduction of dAkt cannot increase the size
of dTsc1 null cells. These observations led Potter et al.
[14] to conclude that “dTsc2 is the critical target for
dAkt in the stimulation of growth in Drosophila”.
How might phosphorylation of TSC2 by Akt down-
regulate TSC1–TSC2? At least four mechanisms are
posited in the recent batch of papers. First, work on
the developing fruit fly eye suggests dAkt overpro-
duction can change the subcellular localization of
dTsc1–dTsc2 [14], which might interfere with the
complex’s function. Second, two groups [10,14] report
that TSC2 phosphorylation by Akt disrupts the
TSC1–TSC2 complex, presumably abolishing its activ-
ity. Other groups [7,12,13], however, failed to detect
this effect, so the relevance of dissociation as a regu-
latory mechanism is not clear. Third, Akt-mediated
phosphorylation of TSC2 also seems to promote
degradation of the complex [7,10]. 
Last, Nellist et al. [13] found that TSC2 can associ-
ate with members of the 14-3-3 protein family, and
that this association is dependent on TSC2 phospho-
rylaton by Akt. Tantalizingly, three of the eight pre-
dicted 14-3-3 binding motifs on TSC2 actually overlap
with Akt phosphorylation sites (including serine 939)
[13]. Binding to 14-3-3 proteins may impinge on a
protein’s function in a variety of ways, such as by
affecting its nucleocytoplasmic localization, targeting
it for degradation, or modifying its protein–protein
interactions. Therefore, Akt-mediated phosphorylation
of TSC2, binding to 14-3-3 proteins and ultimately the
inactivation of the TSC1–TSC2 complex might all be
intimately linked.
Together, these new results suggest the following
model for growth signaling. In the absence of growth-
stimulatory signals, hypophosphorylated TSC1–TSC2
inhibits TOR, so that translation regulated by eIF4E and
S6 kinase is minimal (Figure 1A). When stimulated by
growth factors, activated PI 3-kinase–Akt signal
-ing results in the phosphorylation and inhibition of
TSC1–TSC2 and thus the derepression of TOR (Figure
1B). TOR then phosphorylates S6 kinase and 4E-BP1,
translation rates increase and growth ensues. While
nutritional cues also influence TOR activity, it remains
an open question whether they do this via TSC1–TSC2,
or whether TSC1–TSC2 acts to inhibit the ability of
TOR to respond to nutrients (see above and [8]).
Some other important questions remain unanswered.
For example, are there other regulators of TSC1–TSC2
besides Akt? Are there other TSC1–2 targets in addition
to TOR? And just how important is TSC1–TSC2 in
growth regulation: are all Akt-mediated growth signals
really transduced via TSC1–TSC2 as Potter et al. [14]
claim? While their evidence is persuasive, other data
appear to argue against this conclusion. For instance,
the increased cell size produced by deleting either
dTsc1 or dPTEN is enhanced when both are deleted
simultaneously, suggesting that dPI 3-kinase–dAkt 
signaling can promote growth independently of
dTsc1–dTsc2 [4]. Finally, the global importance of
TSC1–TSC2-mediated signaling to growth regulation in
different in vivo situations remains to be seen.
So TSC1–TSC2 has finally taken its place at the
center of the growth regulatory network, connecting
the nutrient–TOR and PI 3-kinase–Akt growth path-
ways. It is unlikely to rest in peace. No doubt research
is already underway to further characterize the role
and regulation of TSC1–TSC2 both during normal
growth and in disease.
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